Oncology trial operations

Soft tissue sarcoma clinical trial operations

When a soft tissue sarcoma study enrolls a particular histologic subtype, site selection and pathology turnaround can determine whether a referral reaches screening. Define who follows the specimen and who can act when the review slips.

Where study execution gets difficult

Soft tissue sarcoma covers a range of histologies. A hospital with high overall sarcoma volume may still see few patients with the subtype in your protocol. If central confirmation is required, check the referral network, the outside tissue release process, and the reviewing laboratory’s expected turnaround before counting a site toward the enrollment plan.

What the study team can do

Give the site a named contact for outside tissue release. Track requested, dispatched, received, and reviewed as separate milestones. Have the CRA verify the status against site records and the CTM escalate delays that threaten screening or recur across referrals. In perioperative cohorts, use the same discipline for changes to surgery dates and the pathology packet.

When this handoff needs a sponsor decision, use an executive briefing to clarify who owns it and what evidence will guide the decision.

Request an executive briefing →

What each role can own

Oncology CRA

Check retrieval, dispatch, receipt, and review status of the required pathology material at assigned sites.

CTM or Clinical Study Manager

Confirm the referral route, reviewing pathologist, and escalation owner when outside material is delayed.

Cross-site monitoring review

Compare delays from referral, tissue retrieval, central pathology, and dual-marker testing to see which handoffs recur across sites.

A Lead CRA can coordinate recurring findings. For scoped SIGNAL Managed Monitoring, a named review lead brings patterns and open actions to the sponsor’s decision owners.

What to put in the staffing brief

  1. List the permitted subtypes, the sites with a credible referral pathway, and any central confirmation required before enrollment.
  2. Identify who obtains outside slides or blocks, who confirms receipt, and when a pending review reaches the study lead.
  3. Set expectations for CTM ownership of referrals and vendors and CRA follow-up on the evidence each site owes.

Related experience and references

Coordinating a global Phase III sarcoma trial →